Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2016 (2016), Article ID 2168046, 1 page
http://dx.doi.org/10.1155/2016/2168046
Corrigendum

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”

1Cancer Biology Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal
2Molecular Pathology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98, 3000-075 Coimbra, Portugal
3Department of Pathology, Faculty of Medicine of Porto University, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
4Endocrinology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98, 3000-075 Coimbra, Portugal
5Abel Salazar Biomedical Sciences Institute (ICBAS), Lg. Prof. Abel Salazar, 4099-003 Porto, Portugal
6Department of Pathology, Hospital São João, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Received 14 March 2016; Accepted 25 May 2016

Copyright © 2016 Hugo Prazeres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Prazeres, J. Torres, F. Rodrigues et al., “How to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer,” Journal of Thyroid Research, vol. 2011, Article ID 678357, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus